Quick Answer
Aura Biosciences, Inc. reported Net Income of -$106.19 million for fiscal year 2025.
Aura Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$106.19M -22.2% |
-$86.92M -13.8% |
-$76.41M -30.0% |
-$58.76M -66.7% |
-$35.25M -58.7% |
-$22.21M |
| Diluted EPS | -$1.76 -0.6% |
-$1.75 +9.3% |
-$1.93 +1.5% |
-$1.96 +78.1% |
-$8.95 | — |
| Total Assets | $169.43M -7.2% |
$182.50M -28.5% |
$255.07M +13.9% |
$223.94M +39.9% |
$160.03M +624.0% |
$22.10M |
| Cash and Equivalents | $59.52M +87.8% |
$31.69M -22.8% |
$41.06M -66.2% |
$121.58M -18.4% |
$149.06M +757.0% |
$17.39M |
| Stockholders Equity | $136.91M -9.9% |
$151.97M -32.7% |
$225.85M +15.5% |
$195.58M +28.4% |
$152.31M +240.1% |
-$108.71M -24.4% |
| R&D Expense | $90.30M +23.2% |
$73.30M +12.4% |
$65.23M +54.4% |
$42.24M +67.9% |
$25.16M +39.5% |
$18.04M |
| Operating Income | -$112.79M -17.3% |
-$96.12M -13.1% |
-$84.99M -41.0% |
-$60.30M -71.0% |
-$35.25M -58.7% |
-$22.21M |
| Shares Outstanding | 63.59M +27.2% |
50.00M +1.3% |
49.35M +30.7% |
37.77M +29.3% |
29.21M +7564.6% |
381,123 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$26.13M | -24.2% | +3.3% |
| Diluted EPS | September 30, 2025 | -$0.40 | +4.8% | +14.9% |
| Total Assets | September 30, 2025 | $190.02M | -7.5% | -7.0% |
| Cash and Equivalents | September 30, 2025 | $47.55M | +87.2% | -55.7% |
| Stockholders Equity | September 30, 2025 | $156.67M | -10.3% | -10.3% |
| R&D Expense | September 30, 2025 | $22.18M | +30.2% | -3.1% |
| Operating Income | September 30, 2025 | -$27.91M | -20.1% | +2.5% |
| Shares Outstanding | September 30, 2025 | 62.99M | +26.5% | +1.5% |
- Aura Biosciences, Inc. reported Net Income of -$106.19 million for fiscal year 2025.
- Aura Biosciences, Inc. showed a decrease of -22.2% in Net Income compared to the prior fiscal year.
- Aura Biosciences, Inc. reported Diluted EPS of $1.76 per share (loss) for fiscal year 2025.
- Aura Biosciences, Inc. showed a decrease of -0.6% in Diluted EPS compared to the prior fiscal year.
- Aura Biosciences, Inc. reported Total Assets of $169.43 million for fiscal year 2025.
- Aura Biosciences, Inc. showed a decrease of -7.2% in Total Assets compared to the prior fiscal year.
- Aura Biosciences, Inc. reported Cash and Equivalents of $59.52 million for fiscal year 2025.
- Aura Biosciences, Inc. showed an increase of +87.8% in Cash and Equivalents compared to the prior fiscal year.
- Aura Biosciences, Inc. reported Stockholders Equity of $136.91 million for fiscal year 2025.
- Aura Biosciences, Inc. showed a decrease of -9.9% in Stockholders Equity compared to the prior fiscal year.
- Aura Biosciences, Inc. reported R&D Expense of $90.30 million for fiscal year 2025.
- Aura Biosciences, Inc. showed an increase of +23.2% in R&D Expense compared to the prior fiscal year.
- Aura Biosciences, Inc. reported Operating Income of -$112.79 million for fiscal year 2025.
- Aura Biosciences, Inc. showed a decrease of -17.3% in Operating Income compared to the prior fiscal year.
- Aura Biosciences, Inc. reported Shares Outstanding of 63.59 million shares for fiscal year 2025.
- Aura Biosciences, Inc. showed an increase of +27.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: